Stockscreener 앱 받기
2.15
4.87%
-0.11
전일 마감가:
$2.26
열려 있는:
$2.26
하루 거래량:
1.32M
Relative Volume:
0.96
시가총액:
$419.89M
수익:
$7.12M
순이익/손실:
$-24.17M
주가수익비율:
-8.8332
EPS:
-0.2434
순현금흐름:
$-41.95M
1주 성능:
-12.60%
1개월 성능:
-19.78%
6개월 성능:
-23.21%
1년 성능:
+36.94%
1일 변동 폭
$2.11
$2.30
1주일 범위
$2.09
$2.4933
52주 변동 폭
$1.18
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.15 | 419.89M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-15 | 개시 | Wolfe Research | Outperform |
| 2026-10-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-10-06 | 개시 | Guggenheim | Buy |
| 2025-12-11 | 개시 | Roth Capital | Buy |
| 2025-11-17 | 개시 | Leerink Partners | Outperform |
| 2025-10-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-08 | 재개 | B. Riley Securities | Buy |
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo Finance
BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne - GlobeNewswire Inc.
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo! Finance Canada
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo Finance
OVID Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com
H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com Nigeria
Ovid Therapeutics (NasdaqCM:OVID) Stock Forecast & Analyst Predictions - Simply Wall Street
Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus By Investing.com - Investing.com Canada
Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus - Investing.com
Ovid Therapeutics Stock Price Forecast. Should You Buy OVID? - StockInvest.us
September Investor Conferences: Key Catalysts For OVID, Biomea, Nuvectis & More - RTTNews
Ovid management has two September talks scheduled - Stock Titan
Ovid Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades - Stock Titan
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Yahoo Finance
Ovid (OVID) Shares: Posts a 2.19% Gain to $2.80; Range Check: the Supplied Trading Band Runs From $2.66 to $2.94 in the Latest ReadingDividend ETF - vinanet.vn
Ovid (OVID) Momentum: Finishes 2.19% Higher at $2.80 at the Close; Range View: Traders Can Monitor the $2.66-$2.94 Range in the Current UpdateDeath Cross - vinanet.vn
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Balyasny Asset Management L.P. Adds to Ovid Therapeutics Inc (OV - GuruFocus
Ovid (OVID) Quarterly Figures: EPS Prints Above Forecast in the Latest Reading; Investor Response: The Share Price Adds 1.94% in Latest TradingProfit Inflection Point - vinanet.vn
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance
OVID Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 1.07%Earnings Acceleration Picks - vinanet.vn
Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen - marketbeat.com
Morgan Stanley (OVID) investor files to sell 150,000 shares valued at $420,000 - Stock Titan
Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake - Stock Titan
RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants - Stock Titan
Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics - Stock Titan
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Ovid Therapeutics (OVID) sees 4.99% beneficial stake reported by Balyasny group - Stock Titan
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Affinity Asset Advisors (OVID) discloses 15.1M-share Ovid stake with warrant cap - Stock Titan
Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings - MarketBeat
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK
Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Ovid Therapeutics Inc. (OVID) Latest Stock News & Headlines - Yahoo Finance
OVID: Advanced pipeline, strong cash runway, and soticlestat monetization drive future growth - TradingView
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
OVID: Advanced pipeline, strong cash reserves, and expanded leadership drive long-term growth - TradingView
Ovid Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
OVID Looks 59.6% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Ovid Therapeutics Inc. Q2 2026: Revenue $0.7M, EPS $(0.08) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ovid Therapeutics Inc 주식 (OVID) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jeffrey A. Rona | Affiliated Stockholder |
Aug 14 '26 |
Proposed Sale |
2.80 |
150,000 |
420,000 |
0 |
| LEVIN JEREMY M | Executive Chairman |
Mar 23 '26 |
Option Exercise |
1.40 |
47,333 |
66,266 |
3,735,048 |
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
4.22%
자본화:
|
볼륨(24시간):